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Intensive care of the liver transplant patient often begins 
even before an organ donor is found. Bleeding from 
esophageal varices. encephalopathy, intractable ascites. 
and coagulopathy may require intensive care support and 
urgent transplantation. 
For most patients undergoing liver transplantation. the 
first phase of intensive care takes place in the operating 
room where the anesthesia team bears most of the re-
sponsibility for maintaining cardiodynamic stability. re-
placement of blood products, and correction of coagula-
tion disturbances during the long, difficult surgical 
procedure (1,2). 
THE OPERATIVE PROCEDURE 
Liver transplantation takes from 6 to 24 hours to perform 
(average 8 to 10 hours), with blood replacement averaging 
8 to 12 units (range, 2 to more than 200 units). The 
difficulty of the surgery and the blood product require-
ment are dependent upon the original disease process, a 
history of previous surgery, and how well the donor 
organ functions. Diseases such as chronic active hepatitis 
or Laennec's cirrhosis typically increase the difficulty of 
surgery because of the small shrunken liver with thick-
ened, often highly vascularized ligamentous attachments 
and portal hypertension with extensive collaterals in the 
abdominal wall, omentum, hepatic hilum. and pericaval 
retroperitoneal tissues. 
Previous surgery results in highly vascularized adhe-
sions. Small children and infants who have had multiple 
operations in the hepatic hilum for biliarY atresia are 
often the most difficult transplant patients because of 
these dense. highly vascularized adhesions. 
The quality of early graft function is an important factor 
in the amount of blood loss. If early function is poor, a 
protracted coagulopathy may occur that will extend the 
hme required to achieve surgical hemostasis. Usually the 
donor liver will begin making noticeable quantities of bile 
within an hour of revascularization. Failure of the liver 
to make bile is an ominous sign. The thromboelastogram 
has proved to be a valuable tool in the operating room 
for the assessment of the state of coagulation, and helps 
to monitor the need for clotting factors and fibrinolysis 
treatment. 
The routine use of the heparin-free venous bypass 
during the anhepatic phase of the operation has made it 
much easier to maintain hemodvnamic stabilitv during 
the operation, and has also resulted in less blood loss 
(3,4). DecompressIOn of the portal vein prevents massive 
splanchnic venous congestion with oozing from thin-
walled, high-pressure collateral venous channels. De-
compression of the infrahepatic vena cava prevents renal 
venous hypertension, and prevents sequestration of 
blood volume, potassium, and lactic acid in the peripheral 
venous circulation. 
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The use of the venous bypass is limited to p.ltients 
wei~hin~ liver 20 kg. A((t.'ss is diffkult in small d,ildren 
and infants, .mJ tlmv rates .1re low. rK1isin~ the n:;k of 
intravascul.u thrombosis. Fortunatelv. tht.·re is usuallv 
sutficient collaternl circul.ltion in thes-e ~mall patients for 
them to tolerate crossclampin~ of the vena ca\ .. , .1nd 
portal vein without need for bypass. 
All patients .ue kept on a warmin~ blanket during 
sur~ery; blood products and intravenous .md imgation 
fluids are warmed before administration. Nevertheless. 
there is significant loss of body heat during the long 
hours of surgerY. and all patients are hypothermic as 
they arrive in lCU after surgery. Special.,ttention to body 
temperature is required, especially for pediatric recipi-
ents. Since the head accounts for a large percentJge of 
the body surface area in children, simple cellophane 
wrapping of the head will help prevent heat loss. 
ROUTINE POSTOPERATIVE CARE 
Once the patient has arrived in the lCU. strict attention 
is paid to fluid status, electrolyte balance. coagulation, 
liver and kidney function. and cardiopulmonary perform-
ance. Peripheral arterial. pulmonary artery wedge, and 
central venous pressures, arterial blood gases, cardiac 
rhvthm and output. urine volume, and surgical drains 
are all monitored doselv. 
CBC, prothrombin time, partial thromboplastin time, 
platelets, sodium. potassium. chloride. and bicarbonate 
are monitored frequently. BUN, creatinine, calcium. 
phosphorus. bilirubin (total and direct)' SGOT, SGPT, 
alkaline phosphatase. gamma GTP. amylase, and albumin 
are measured at least dailv. In children, low serum 
calcium and magnesium are frequently seen. and must 
be promptly treated to prevent severe coagulation and 
CNS complications. 
A nasogastric tube is kept to low continuous suction 
and irrigated hourly with saline. Antacid (Mylanta, 30 
mil is administered via the nasogastric tube every 4 hours. 
The patient is turned every 2 hours and postural drainage 
and dapping is done every 4 hours. 
Antibiotics with a spectrum appropriate for biliary tract 
pathogens (Klebsiella. E. coli, and Enterococcus) are admin-
istered preoperatively and continued for 5 days after 
surgery. Ampidllin and cefotaxime, each given as one 
gram every 6 hours, has been our traditional regimen. 
Immunosuppression is begun perioperatively. The first 
dose of cydosporine is given orally, 17.5 mg/kg, just prior 
to surgery. Patients receive 1 gram of intravenous meth-
ylprednisolone at the time the graft is first revascularized. 
Postoperatively, cydosporine is given as 2 mg/kg intra-
venously every 8 hours until the patient resumes oral 
intake. At this time oral cydosporine, 17.5 mg.'kg, is 
given in a divided dose every 12 hours and the intrave-
nous therapy is reduced to twice a dav. Blood trough 
levels of cydosponne are monitored dailv and the dosages 
adjusted accordingly to maintain therapeutic levels and 
minimize toxicity. Prednisone is admmistered starting at 
200 mg on the first day in four divided doses. and is 
tapered by 40 mg/dav until a maintenance dose of 20 mg! 
dav is reached. In children weIghing less than 30 kg. the 
dose of steroid is begun as 100 mg/day in four divided 
doses, and is tapered by 20 mg/day unnl a maintenance 
dose of 10 to 20 mg/day is reached. 
Patients with poor renal function after surgery may be 
unable to tolerate conventional doses of cydosporine. For 
these patients, the dose is reduced or cydosporme may 
be temporarily withheld and treatment with another 
---- ~--~---
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l~cnt sub~titutcdK Antilymphocyte antibody prepara-
:ions, espccially OKT, monoclonal antibodv (Ortho Phar-
n;]ccutic;]ls. Rilritan, NJ), have been most trequently used 
or this situation as well as for the treatment of steroid-
'csistant rejection (5,6). 
Oral and vaginal candidiasis are frequent problems in 
mmunosuppressed patients. Mycostatin oral suspension 
, gwen four times a day, and for female patients, 
nvcostatin vaginal suppositories are also given three 
Imes a dav. 
Fluid management in the early postoperative period is 
larticularly important. Most patients arrive in the ICU 
vith a much expanded extracellular fluid volume. Oex-
~oseI 5% in 112 normal saline, is infused intravenouslv 
t 125 ml per hour. Excessive use of crystalloid can easily 
~sult in pulmonary edema. Plasma protein fraction or 
-esh frozen plasma is used to provide oncotic pressure 
nd support volume. The central venous pressure is 
1aintained at about 10 em H10, and the urine output is 
1aintained at 0.5 mllkg-h. Hypovolemia must be avoided, 
5 the combination of hypovolemia and cyclosporine may 
~sult in acute renal tubular necrosis. 
Fluid replacement must be appropriately adjusted in 
lildren. A formula based on weight is followed in which 
)0 mllkg for the first 10 kg, 50 m1Ikg for the second 10 
~I and 20 mllkg for weight in excess of 20 kg is given 
~r dav. 
Aggl-essive correction of abnormal clotting parameters 
:n be harmful and may precipitate hepatic artery throm-
)sis (7), We do not attempt to correct the prothrombin 
ne unless it is greater than 25 seconds or there is 
~ificant clinical evidence of ongoing blood loss. The 
atelet count is frequently low after surgery; again, we 
) not treat unless the count is below 50,000 mmJ or 
eeding is a significant problem. Dextran 40, given at 20 
Uh for the first 100 hours after surgery, may be helpful 
preventing hepatic arterial thrombosis. 
Narcotics and sleep medications are generally avoided, 
these medications depend upon hepatic metabolism. 
children, smail doses of morphine sulfate may be given 
irequently. 
\iost patients can be extubated within 36 hours of 
eration. An aggressive pulmonary regimen is main-
ned with frequent suctioning, turning, cupping, pos-
,al dramage, incentive spirometry, and early mobiliza-
n. Atelectasis is treated promptly with reauitment and, 
leeded, bronchoscopy. 
'f there are no special problems or complications, the 
tient is usually ready for transfer to the regular surgical 
or on the second or third postoperative day. 
)MPLICATIONS AFTER lIVER TRANSPlANTATION 
,monary Complications 
~ most common problems in the early postoperative 
'wd are respiratory, especially atelectasis and pleural 
lsion. AtelectaSIs may easily progress to lobar collapse, 
~ even limited atelectaSIs can easily lead to pneumonia 
the immunosuppressed patient and must be treated 
;resslVely. A decision for early reintubation must be 
ed not only on the patient's general overall status but 
) on the function of the newly transplanted liver. 
quent nasotracheal suctiomng can result in serious 
D~dingK 
\nother very common problem is that of pleural effu-
~pI parncularly on the right side. When the suprahe-
IC cava is clamped, of necessity a portion of the right 
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flfDmlliiaphra~tn is usually includ.cd in the clam 
this promotes the dcvelopent ot ,\ ri~ht-sided Pi and 
effuslllO. Less otten. ,1 right phrenic palsy may als: eUrai 
from (rush injurY to the nerve. A small pleural ef~ult 
will oiten resolve after ~everal days ot effective diu 51-:,n 
If they are lar~eI however, the,se effUSions phoul:r~ 
drained to prevent pneumoma In the underlYing c 
presst!d lung. Great care must be taken in the placemom-
of a chest tube. especially if the patient's coagulatient 
profile is abnormal. These patients often have enlar : 
intercostal collateral vessels that can result in catastropghi 
bleeding if injured. A small, pigtail catheter, which .r: 
placed using guidewire technique, is a safe, effective wa~ 
to obtain drainage. 
A curious pulmonary Kcomplica~on that occasionally 
occurs IS seve~e metabo~lc ~fkalosls WIth compensatorY 
respiratory aCidOSIS. This IS usually seen in cases of 
primary graft failure. If the patient is awake and making 
urine, the liver will usually recover. 
Primary Graft failure 
Urgent retransplantation of the liver is required if the 
gratt fails to function. Primary graft failure presents with 
a variety of problems. In its mildest form it presents with 
decreased quality and quantity of bile, decreased urine 
output with increasing serum creatinine, increased arte-
rial pH and mCl~I and elevated hepatic transaminases. 
The patient nevertheless shows minimal ill effects and 
improves as the liver recovers. In severe cases. the patient 
remains comatose, anuric, and alkalotic. Prothrombin 
times are markedly prolonged and serum transaminases 
in the 5,000 to 10,000 IU range may be seen. The ammonia 
level is markedly increased, and pH and HCOl levels are 
in the 7.60 and 35 to 45 mEq/L range, respectively. 
Infusion of 0.2 N HO is required to maintain acceptable 
blood pH. Acetazolamide cannot be used because of poor 
renal function, and dialysiS may be required. Hyperten-
sion must be prevented since these patients are at high 
risk for intracerebral hemorrhage. The blood glucose, 
which may be high initially, falls to dangerous levels, 
requiring infusion of hypertonic glucose. Prompt retrans-
plantation, crossing ABO blood groups if necessary, is 
the only way to save these patients (8). 
Severe, Earty Rejection 
Hyperacute, antibody-mediated rejection of the liver, if 
it occurs at all, is a rare event, but accelerated cell-
mediated rejection does occur and can be severe enough 
to require early retransplantation (9). It presents 48 to 72 
hours after transplantation, and is characterized by an 
increase in prothrombin time, bilirubin, and liver en-
zymes. A cholangiogram and ultrasound are obtamed to 
rule out biliarY tract complications or vascular aCC1dents. 
It mav be difficult to differentiate ischemic injury from 
early rejection without a liver biopsy; however, t~e pro-
longed prothrombin time and thrombocytopema may 
make biopsy hazardous. 
More common lv, acute cellular rejection presents 10 to 
14 days after transplantation with elevated bilirub,in, With 
or without elevated transaminases. A needle bIOpsy IS 
almost always pOSSible and confirms the diagnosis. The 
first treatment of acute rejection is high-dose sterOids, 
but if there is not a prompt response, OKT3. a mU!lne 
antihuman T-cell monoclonal antibodv, is our treatmehnt 
of chOice and will reverse rejection in'70% to 80% of t e 
cases (5,6). 
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CARE OF THE LIVER TRANSrLANT PATIENT 
~ftKsDUfDpliol:l·"~D Disease 
transplantation of the liver is done across ABO blood 
the transplant~d liver mny produce nntibodies to 
ABO nntigens. This may cnuse n mild. short-
gratt-versus-host reaction manifested by hemolytic 
with or WIthout thrombocytopema and/or leuco-
(8.9). Transfusion support may be required for a 
period. Splenectomy was reqUired in one case in 
experience tor retractory thrombocytopenia. 
thrombosis complicates approximately 7% of the' 
transplants and is most common in children. espe-
infants (10) (Marsh et al.. unpublished observa-
Unexplained fever and sepsis with or without an 
il.tt'1l'f>a!ie in hepatic transaminases is the hallmark. and a 
1nKKI~ .. I, .. r ultrasound is almost always diagnostic (11). If 
artery pulsations cannot be clearly identified. an 
r.rtericlgram is indicated. Bile leak. bile peritonitis. or 
tic bile abscess may result from the ischemic 
to the bile duct system. Blood and bile (if a T tube 
...... ' .. ntl are cultured. and broad-spectrum antibiotics 
begun. Liver abscesses can often be drained percu-
Many patients. especially children. can be 
'_.,inj''''r,pn on conservative therapy for many months. 
virtuallY all will eventually require retranspiantation 
of irreversible ischemic injury to the biliary tract. 
patients will present with frank hepatic gangrene 
, urgent retransplantation. 
vein thrombosis is rare. Patients at highest risk 
very small children (weight less than 10 kg) with 
portal veins. and adults with low flow 
I"r1"fl~Ill the portal vein secondary to previous thrombo-
pruleOI:hS. or portosystemic shunts. Acute portal vein 
uu"uU'U""" is usually a catastrophic event. with bacterial 
fungal sepsis and severe liver failure. 
BlI10ry ComplicatiOns 
leaks or strictures are the most common biliarv 
lOJl'lpU.catlonls (12). Bile leaks at the anastomosis or from 
insertion site typically present with fever. chills. 
upper quadrant pain. sepsis. increased serum bili-
bilious drainage. or Candida cultured from the 
, drains. In the absence of systemic candidiasis. 
positive Candida culture from an abdominal drain in-
, means a bile or bowel leak. cr scans have been 
in making this diagnosis. and the absence of 
enteric pathogens in cultures can also be misleading. 
Surgical correction of the leak is required. A leak from a 
-tube insertion site can often be fixed by simple suture 
reinforcement. but a leak from a duct-to-duct reconstruc-
tion requires conversion to a Roux-en-Y choledochojeju-
Bile duct strictures are usually late complications from 
. . injury to the biliary tree. premature removal of 
the T-tube or biliary stent. or the normal cicatricial healing 
~essK Percutaneous dilation may relieve the stricture. 
t Usually definitive surgical revision is ultimately re-
quued (12). 
Again. it is emphasized that biliary tract complications 
~_ of,ten secondary to hepatic arterial thrombosis. and 
uus diagnosis must always be suspected and ruled out. 
Acute renal failure after liver transplantation is much less 
COrnman since the routine use of the venous bypass was 
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instituted. Hmvcvcr. ,l(utl! renal tailure still ~umplkates 
cases with sevcre pre-existing renal discllse. hep,ltorcnal 
syndrome. cvdosporine tllxicity. dm~ reactiun. Ilr, must 
communlv. ,lcote tubul.tr necrosis. 
Pre-existing hepatorenal syndrome is common and 
usually resolves rather lluickly in. the presence Ili ~ood 
grait tunction. Paticnts whose gratts tail to functiun well 
,lre usually oliguric or anuric until the graft recovers 
function or until the pntient is successfullv retrans-
planted. Simultaneous liver-kidney trnnsplantation has 
been performed in ten ot our cases tor patients on dialysis 
with chronic renal failure from liver disease or from 
intrinsic renal disease. 
Cyclosporine toxicity is difficult to distinguish clinically 
from acute tubular necrosis. It commonly presents in the 
early postoperative period while patients are on intrave-
nous cyclosporine but certainly can occur in patients 
taking only oral cyclosporine. Acute tubular necrosis 
usually occurs in the intraoperative setting of hypotension 
~nd massive transfusions. It is exacerbated by cyclospor-
ine (and other nephrotoxic drugs) and is likely to resolve 
more quickly if cyclosporine dosage is reduced (13). Early 
dialysis is instituted if needed . 
Nervous System Complications 
Problems of the nervous svstem are often perplexing and 
difficult to deal with. These include seizures. strokes. 
"dulled mentation." peripheral neuropathy. and brachial 
plexus injuries. 
Seizures are the most common neurolOgical complica-
tion. are more common in children than in adults. and 
are usually grand mal in type. cr scan and lumbar 
puncture are usually negative and the need for further 
treatment is unusual. Occasionally. patients will have 
seizures due to an intracranial bleed. hyponatremia. or 
cyclosporine combined with hypervolemia. If cyclospor-
ine toxicity is suspected. it is not necessary to discontinue 
the drug. but reduction in dosage is prudent. If there is 
no metabolic or anatomical abnormality. the seizures 
usually do not recur. -
Intracranial bleeding is a rare but devastating event. It 
usually happens early in the postoperative period while 
the patient is hypertenSive and still has a relative coagu-
[opathy. Strict attention must be given to postoperative 
hypertension. aVOiding mean arterial pressures above 100 
mm Hg in adults and 90 mm Hg in children. 
"Dulled mentation" is mentioned for lack of a better 
term. Some patients. especially those with Laennec's 
cirrhOSIS. are often very slow to return to their preoper-
ative mental status baseline. Fortunately. eventual com-
plete return is usually achieved. Confusion. disorienta-
tion. and delirium result from cyclosporine toxicity, 
especially in older patients. 
Peripheral neuropathy may result from toxic doses of 
cyclosporine. It is usually limited to the lower extremities 
and can range from mild tingling to severe sensory and 
motor dysfunction. A reduction tn cyclosporine dosage 
is all that is reqUired. but other causes such as the 
Guillain-Barre syndrome should be ruled out. 
Brachial plexus injuries are rare and can result from 
stretch or direct injury during dissection of the aXIllary 
vein. Simple stretch injuries from prolonged hyperexten-
sion of the arm are almost always partial. and full recov-
ery can be expected with time. Nerve conduction studies 
are helpful in reassuring the patient that the nerves are 
intact and that function will return. 
Surgical injury to the brachial plexus can be stretch. 
thermal. or crush injury, or a complete or partial transec-
tion. Recovery depends upon the nature of the injury. 
Postoperative Infection 
Infection is the most common postoperative cause of 
death after liver transplantation (14). Infections early in 
the postoperative period are rare and limited mostly to 
wound infections, especially in children with a previous 
enterostomy from a Kasai procedure. It is in this same 
group of children that the dreaded late complication of 
infected and ruptured vascular grafts occurs. It is there-
fore preferable that enterostomies be closed prior to 
transplantation. In adults, wound infections are quite 
rare and usually occur subsequent to intra-abdominal 
infections such as from bowel or bile leaks. As previously 
mentioned, CT scans have not been reliable in detecting 
either of these complications. Prompt reoperation is in-
dicated if either is suspected. Positive cultures for Candida 
in closed abdominal drains are a strong indication for 
abdominal exploration. 
Bacterial pneumonia is fairly uncommon but there is a 
predisposition to it in adults with pre-existing lung dis-
ease (chronic bronchitis, emphysema, cystic fibrosis, and 
alpha-l-antitrypsin deficiency). Antibiotic treatment is 
based on the results of specific cultures. 
Occasionally, it is learned that the donor had a positive 
blood culture. In these cases, especially for Gram-negative 
infections, the recipient is treated as though he or she, 
too, were positive for this organism. 
Viral screening is routinely performed, but it is rare to 
find evidence of viral infection early after surgery. Posi-
tive titers for cytomegalovirus (CMV) are common after 
the first month and can result from new infection or 
reactivation. CMV-positive donors, whenever possible, 
are used only for CMV-positive recipients. 
Of the three most common viral infections, CMV, 
herpes simplex virus (HSV), and Epstein-Barr virus 
(EBV), CMV is the most prevalent (Breinig et aI., Ho et 
al.. and Makowku et aI., unpublished observations). 
CMV infection is characterized bv fever, malaise. ano-
rexia, abnormal liver function tests (bilirubin. trans ami-
nases). and leucopenia. Steroids are reduced to a minimal 
dose (5 to 10 mglday), and cyclosporine is reduced 
modestly. Severe cases of fulminant viral hepatitis, with 
or without pneumonitis. duodenitis, gastritis, and colitis, 
usually require withdrawal of all immunosuppression. 
The virus itself has an immunosuppressive effect and 
fulminant rejection is Tare. Failure to promptly withdraw 
immunosuppression in the face of severe, systemic viral 
infection is fatal. The severe leucopenia that is often seen 
with viral infections can lead to secondary bacterial infec-
tion. If immunosuppression is withdrawn early enough, 
complete recovery is often possible. In some cases, over-
whelming hepatitis has been successfully managed by 
retransplantation. 
Occasionally. in patients without any clinical symptoms 
of viral infection. evidence of virus is found on liver 
biopsy. usually in conjunction with rejection. In this 
setting. the virus is usually ignored and the patient is 
treated for rejection. 
We have had little experience with DHPG for the 
treatment of CMV infection. It seems useful for the 
treatment of CMV retinitis and GI infections. but results 
for hepatitis, encephalitis. and pneumonitis have been 
disappointing (15). 
Herpetic infections range from rises in titers alone to 
skin lesions, hepatitis, or encephalitis. Any sign of HSV 
TRANSPLANTA nON 
infe~tion should be ftr~ated withbacycluvidr. Li.mited. ac-
cessible cutaneous eSlUns can e treate With topic I 
cream but other lesions require systemic therapy. tit~_ 
drawal of immunosuppressiun is based on the clinical 
severity of the disease. Herpes encephalitis has bee 
uniformly fatal. even with acyclovir and the tithdraw~ 
of immunosuppression. 
EBV infections are t~e le~st ~ften appreciated and range 
from asymptomatic nses In titers, to a mononucleosis-
like picture, to true lymphoma (16). All EBV infeCtions 
are treated with acyclovir. Patients presenting with lym_ 
phadenopathy or masses suspicious of a pseudo or true 
lymphoma should be biopsied to determine the clonalitv 
of the tumor. Acyclovir, surgical resection, and With-
drawal of immunosuppression are the treatment options 
depending upon the stage of the disease (17). Since w~ 
believe that these lesions are an iatrogenic complication 
of immunosuppression, the withdrawal of immuno-
suppression rather than chemotherapy is the proper 
approach to management. 
Fungemia, particularly with Candida albicans, is an all 
too frequent manifestation of an overcompromised host. 
We recommend that patients who have had long opera-
tions with large amounts of blood replacement or signif-
icant violations of the GI tract also be considered for 6 
weeks of maintenance therapy with amphotericin (10 to 
15 mg per day). Patients with established systemic un-
dida infections may require higher dose therapy (25 to 30 
mglday). Positive blood cultures should not be dismissed 
as "line sepsis." The dose of amphotericin is adjusted to 
accommodate the level of renal function. 
Pneumocystis pneumonia is the most common life-
threatening, opportunistic, nonviral infection. Treatment 
with trimethoprimlsulfamethoxazole (TMP/SMX) should 
be begun on suspicion. Bronchoalveolar lavage is helpful 
in establishing the diagnosis (18,19). Open-lung biopsy 
is reserved only for cases in which the diagnOSiS is unclear 
and it is dangerous in patients requiring high levels of 
positive end-expiratory pressure (PEEP) to maintain ox-
ygenation. immunosuppression should be severely re-
duced or withdrawn until significant clinical improve-
ment occurs. Pentamidine can be used instead of TMPI 
SMX in patients with resistant infections or allergy to 
sulfa drugs. Prophylaxis with TMP/SMX is effective in 
reducing the incidence of Pneumocystis infection in the 
immunosuppressed patient. 
CONCLUSION 
The care of the liver transplant patient is formidable but 
highly rewarding. With proper care, the typical patient 
will recover rapidly and intensive care is required only 
for the first few days after surgery. However, when 
problems do occur. care of these patients requires the 
highest level of skill and dedication. 
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INTRODUCTION 
In June 1986, the United States Congress authorized 
Medicare to provide financial coverage for patients in 
need of cardiac transplantation who were covered by this 
agency. In this way. cardiac transplantation was given 
the same official recognition, as a therapeutic modality, 
that was given to renal transplantation for the treatment 
of end-stage renal failure in 1971. This Federal interven-
tion came when there had already been an incredible 
proliferation of heart transplant centers in the United 
States. In 1980. there were six medical centers in which 
this procedure was performed_ By June 1986, this number 
had increased to about 90. If it is exciting to see an 
increasing enthusiasm for heart transplantation. and if 
We do agree that this procedure should be performed in 
many medical centers in order to make it available for a 
larger number of patients, we also believe that a few 
centers in the United States should continue to display a 
particular commitment to the experimental and clinical 
research in heart transplantation in order to improve the 
knowledge in this field of transplantation which, in many 
aspects, has not been explored. 
In this chapter we will present the historic backgn1und, 
experimental and clinical. ,Uld the prescnt state ot the art 
of cardiac transplantation. The present indications. the 
surgical technique, the postoperative management. and 
the results will be presented, referring in particular to the 
Pittsburgh experience. 
HISTORICAL BACKGROUND 
Clinical cardiac transplantation flourished from the ex-
perimental work of Lower and Shumway (1). More than 
20 years ago, they developed in a dog model a surgical 
technique for orthotopic cardiac transplantation that. with 
only slight modification, is still used. Christian Barnard 
in December 1967 performed the first human heart trans-
plant in Capetown (2). This event was followed in the 
United States by a period of great enthusiasm during 
which the procedure was attempted in several centers. 
In January 1968, Shumway et al. (3) performed the first 
cardiac transplant in the United States and were followed 
by Cooley et al. (4), who performed their first successful 
transplant in May 1968. This enthusiasm was of short 
duration because the results were drastically hampered 
by an excessive short-term mortality related to an uncon-
trollable rate of infections or rejection. As a consequence 
of these poor results, clinical experimentation was contin-
ued during the 1970s in only a few centers and, in 
particular, at Stanford University. In the late 1970s at 
Stanford. with the introduction of cyclosporine as a new 
immunosuppressive agent, improvement in the 1- and 5-
year survival rates to 65% and 40%, respectively, resulted 
in the consideration that transplantation was no longer 
experimental, but therapeutic. 
As a consequence of these improved results, a renewed 
interest in the procedure came about; since 1980, the 
number of centers performing cardiac transplantations 
has been steadily increasing (Fig_ 142-1). The number of • 
potential candidates seems to increase as the indications 
for the procedure widen. It is estimated that. in the 
United States, 4000 patients per year could benefit from 
cardiac transplantation. If the proliferation of heart trans-
plant centers should be welcomed as a way to make this 
procedure more; easily available to a larger number of 
patients, the care of the heart transplant recipient requires 
such a multidisciplinary approach that the cost effective-
ness of performing only a few procedures per year in any 
center must be considered, especially in a time when 
funds for medical care seem to be limited and waning. 
We will leave aside these medico-economic considerations 
and focus on the medical aspects of cardiac transplanta-
tion. 
PATIENT SElECTION 
The classic indications for cardiac transplantation have 
been end-stage ischemic or idiopathic cardiomyopathy, 
eqUivalent to Class IV categorization by the New York 
Heart Association. While early in our experience idio-
pathic cardiomyopathy was the prevalent indication. 
since 1984 older patients have been treated. and ischemic 
cardiomyopathy has been more common (Fig. 142-2). 
Most patients with ischemic cardiomyopathy have had 
one or two previous coronary artery bypasses. Of 204 
patients who underwent cardiac transplantation between 
July 1982 and June 1986, 110 had ischemic cardiomyopa-
thy and 74 had idiopathic cardiomyopathy (Table 142-1). 
We have included patients with end-stage valvular heart 
disease (n = 12), isolated amyloidosis (n = 1), and sarcoid-
